Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial
Open Access
- 1 January 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 14 (2), R41
- https://doi.org/10.1186/cc8924
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin prophylaxis: prevalence, incidence and risk factorsCritical Care, 2008
- Preventing Venous Thromboembolism in Medical PatientsCirculation, 2004
- Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?*Critical Care Medicine, 2003
- Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparinThrombosis Research, 2002
- Anticoagulation TherapyHematology-American Society Hematology Education Program, 2001
- Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolismPublished by Wiley ,1999
- A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical PatientsNew England Journal of Medicine, 1999
- Occurrence of thrombosis and haemorrhage, relationship with anti‐Xa, anti‐IIa activities, and D‐dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgeryBritish Journal of Haematology, 1999
- Low Molecular Weight HeparinAnesthesia & Analgesia, 1997
- Diagnostic Significance of Thrombin-Antithrombin III Complex (TAT) and D-Dimer in Patients With Deep Venous ThrombosisJapanese Circulation Journal, 1996